Disease · HP_0100806

Sepsis

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. Sepsis. Diseases, record HP_0100806. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0100806

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: Sepsis
Open Targets ID: HP_0100806
Other names: BLOOD POIS, Blood Poisoning, Blood Poisonings, Infection in blood stream, POIS BLOOD, Poisoning, Blood, Poisonings, Blood, Pyaemia, Pyaemias, Pyemia, Pyemias, Pyohemia, Pyohemias, Sepsis, NOS, Sepsis, Severe, Septicaemia, NOS, Septicemia, Septicemia, NOS, Septicemias, Severe Sepsis, Systemic infection, Systemic infection (disorder), Systemic infection, NOS, toxemia
Highest stage of its drugs: Approval, for 27 of its 231 drugs, from DailyMed, FDA, PMDA and TTD

Source Open Targets

Drugs231

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
PIPERACILLIN	CHEMBL702	Small molecule	Approval	PMDA	12	11	10	Drugs and targets
TAZOBACTAM	CHEMBL404	Small molecule	Approval	PMDA	11	10	9	Drugs and targets
DROTRECOGIN ALFA (ACTIVATED)	CHEMBL2109065	Protein	Approval	TTD	11	9	9	Drugs and targets
NOREPINEPHRINE	CHEMBL1437	Small molecule	Approval	TTD	10	9	9	Drugs and targets
VANCOMYCIN	CHEMBL262777	Small molecule	Approval	FDA	6	5	5	Drugs and targets
IMIPENEM	CHEMBL43708	Small molecule	Approval	DailyMed	12	4	4	Drugs and targets
CEFTAZIDIME	CHEMBL44354	Small molecule	Approval	PMDA	5	4	4	Drugs and targets
METRONIDAZOLE	CHEMBL137	Small molecule	Approval	DailyMed	31	3	3	Drugs and targets
DAPTOMYCIN	CHEMBL387675	Small molecule	Approval	PMDA	4	3	3	Drugs and targets
AZTREONAM	CHEMBL158	Small molecule	Approval	DailyMed	6	1	1	Drugs and targets

1 to 10 of 231

See all 231 drugs

Targets217

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
GABRA1	GABA-A receptor; anion channel	8	GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Phase 3	https://conductscience.org/library/genes/2554	Drugs and targets
GABRA2	GABA-A receptor; anion channel	8	GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Phase 3	https://conductscience.org/library/genes/2555	Drugs and targets
GABRA3	GABA-A receptor; anion channel	8	GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Phase 3	https://conductscience.org/library/genes/2556	Drugs and targets
GABRA4	GABA-A receptor; anion channel	8	GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Phase 3	https://conductscience.org/library/genes/2557	Drugs and targets
GABRA5	GABA-A receptor; anion channel	8	GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Phase 3	https://conductscience.org/library/genes/2558	Drugs and targets
GABRA6	GABA-A receptor; anion channel	8	GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Phase 3	https://conductscience.org/library/genes/2559	Drugs and targets
GABRB1	GABA-A receptor; anion channel	8	GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Phase 3	https://conductscience.org/library/genes/2560	Drugs and targets
GABRB2	GABA-A receptor; anion channel	8	GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Phase 3	https://conductscience.org/library/genes/2561	Drugs and targets
GABRB3	GABA-A receptor; anion channel	8	GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Phase 3	https://conductscience.org/library/genes/2562	Drugs and targets
GABRD	GABA-A receptor; anion channel	8	GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Phase 3	https://conductscience.org/library/genes/2563	Drugs and targets

1 to 10 of 217

See all 217 targets

Trials263

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 11 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01598831	Phase 3 Safety and Efficacy Study of ART-123 in Subjects With Severe Sepsis and Coagulopathy	Phase 3	816	2020-04-21	Severe Sepsis, Coagulopathy	THROMBOMODULIN ALFA	Its record names the disease	ClinicalTrials.gov
NCT03509350	Vitamin C, Thiamine, and Steroids in Sepsis	Phase 3	501	2020-09-18	Sepsis	ASCORBIC ACID, HYDROCORTISONE, THIAMINE	Its record names the disease	ClinicalTrials.gov
NCT04291508	Acetaminophen and Ascorbate in Sepsis: Targeted Therapy to Enhance Recovery	Phase 2	488	2024-09-27	Acute Respiratory Distress Syndrome, Critical Illness, Respiratory Failure, Sepsis	ACETAMINOPHEN	Its record names the disease	ClinicalTrials.gov
NCT00386425	Evaluate Protein C Levels in Severe Sepsis Patients on Drotrecogin Alfa (Activated)	Phase 2	486	2010-12-16	Severe Sepsis	DROTRECOGIN ALFA (ACTIVATED)	Its record names the disease	ClinicalTrials.gov
NCT01739933	The MENDS2 Study, Maximizing the Efficacy of Sedation and Reducing Neurological Dysfunction and Mortality in Septic Patients With Acute Respiratory Failure	Phase 3	438	2021-06-07	Sepsis, Delirium, Impaired Cognition	DEXMEDETOMIDINE, PROPOFOL	Its record names the disease	ClinicalTrials.gov
NCT03019965	Efficacy of Betalactam Antibiotics in Prolonged Infusion Compared to Intermittent in Pediatric Patients With Sepsis	Not applicable	426	2021-08-05	Sepsis	IMIPENEM, MEROPENEM, PIPERACILLIN, TAZOBACTAM	Its record names the disease	ClinicalTrials.gov
NCT04540094	Feasibility of 5% Albumin Compared With Balanced Crystalloid, as Intravenous Fluid Resuscitation in Adult Patients With Sepsis, Presenting as an Emergency to Hospital	Phase 3	300	2024-10-04	Sepsis	ALBUMIN HUMAN	Its record names the disease	ClinicalTrials.gov
NCT03389555	Ascorbic Acid, Corticosteroids, and Thiamine in Sepsis (ACTS) Trial	Phase 2/3	205	2021-01-29	Sepsis, Septic Shock, Metabolic Disturbance	ASCORBIC ACID, HYDROCORTISONE, THIAMINE	Its record names the disease	ClinicalTrials.gov
NCT00464204	Effects of Voluven on Hemodynamics and Tolerability of Enteral Nutrition in Patients With Severe Sepsis	Phase 3	196	2011-08-02	Sepsis	HYDROXYETHYL STARCH 130/0.4, SODIUM CHLORIDE	Its record names the disease	ClinicalTrials.gov
NCT02106975	Vitamin C Infusion for Treatment in Sepsis Induced Acute Lung Injury	Phase 2	170	2019-10-15	Acute Lung Injury, Sepsis	ASCORBIC ACID	Its record names the disease	ClinicalTrials.gov

1 to 10 of 263

See all 263 trials

Comparisons in its trials90

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
ART-123 vs Placebo: Number of Participants With Anti-drug Antibodies	0 of 396	0 of 404	800	NCT01598831	Trial comparisons
ART-123 vs Placebo: Follow up All-cause Mortality at 3 Months	126 of 395	136 of 405	800	NCT01598831	Trial comparisons
ART-123 vs Placebo: Number of Participants With On-Treatment Serious Major Bleeding Events	23 of 396	16 of 404	800	NCT01598831	Trial comparisons
ART-123 vs Placebo: deaths from any cause	141 of 395	148 of 405	800	NCT01598831	Trial comparisons
ART-123 vs Placebo: Number of Participants With 28-Day All-cause Mortality	106 of 395	119 of 405	800	NCT01598831	Trial comparisons
ART-123 vs Placebo: serious adverse events	206 of 396	202 of 404	800	NCT01598831	Trial comparisons
ART-123 vs Placebo: Day 28 Mortality in Subjects With INR > 1.4 at Baseline and PLT > 30K at Baseline	82 of 307	105 of 327	634	NCT01598831	Trial comparisons
Treatment Protocol vs Control Protocol: Intensive Care Unit (ICU) Mortality	52 of 252	49 of 249	501	NCT03509350	Trial comparisons
Treatment Protocol vs Control Protocol: Mortality at 30 Days	56 of 252	60 of 249	501	NCT03509350	Trial comparisons
Treatment Protocol vs Control Protocol: deaths from any cause	102 of 252	94 of 249	501	NCT03509350	Trial comparisons

1 to 10 of 90

See all 90 comparisons in its trials

Papers from its trials322

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
42573415	RESULT	1	PubMed
38691102	RESULT	2	PubMed
38688665	RESULT	1	PubMed
38240494	RESULT	1	PubMed
36915146	RESULT	1	PubMed
36705345	RESULT	1	PubMed
36237547	RESULT	1	PubMed
36174744	RESULT	1	PubMed
34719443	RESULT	1	PubMed
34333556	RESULT	1	PubMed

1 to 10 of 322

See all 322 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/HP_0100806

GET https://conductscience.org/api/diseases/v1/HP_0100806/drugs?page=2

API reference For AI assistants